东诚药业(002675.SZ)：达肝素钠注射液增加规格获批上市

Core Viewpoint - Dongcheng Pharmaceutical (002675.SZ) announced that its wholly-owned subsidiary, Yantai Dongcheng Northern Pharmaceutical Co., Ltd., received a notification from the National Medical Products Administration regarding the approval of a new specification (0.2ml: 5000AXaIU) for its low molecular heparin product, Dalteparin Sodium Injection [1] Group 1: Product Information - Dalteparin Sodium Injection is a low molecular weight heparin preparation with anticoagulant properties, primarily indicated for the treatment of acute deep vein thrombosis [1] - The product is also used to prevent acute renal failure or chronic renal insufficiency during hemodialysis and blood filtration, as well as to treat unstable coronary artery diseases such as unstable angina and non-Q wave myocardial infarction [1] - Additionally, it is indicated for the prevention of thromboembolism associated with surgical procedures [1]